Concert Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CNCE and buy or sell other stocks, ETFs, and their options commission-free!About CNCE
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders.
CEORoger D. Tung, PhD
CEORoger D. Tung, PhD
Employees—
Employees—
HeadquartersLexington, Massachusetts
HeadquartersLexington, Massachusetts
Founded2006
Founded2006
Employees—
Employees—
CNCE Key Statistics
Market cap401.95M
Market cap401.95M
Price-Earnings ratio-2.61
Price-Earnings ratio-2.61
Dividend yield—
Dividend yield—
Average volume2.51M
Average volume2.51M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$8.55
52 Week high$8.55
52 Week low$2.66
52 Week low$2.66
Stock Snapshot
The current Concert Pharmaceuticals(CNCE) stock price is $8.37, with a market capitalization of 401.95M. The stock trades at a price-to-earnings (P/E) ratio of -2.61.
Concert Pharmaceuticals(CNCE) stock opened on 2025-12-17 at —. The price climbed to — and dipped to —.
Concert Pharmaceuticals(CNCE) shares are trading with a volume of 0, against a daily average of 2.51M.
In the last year, Concert Pharmaceuticals(CNCE) shares hit a 52-week high of $8.55 and a 52-week low of $2.66.
In the last year, Concert Pharmaceuticals(CNCE) shares hit a 52-week high of $8.55 and a 52-week low of $2.66.
People also own
Based on the portfolios of people who own CNCE. This list is generated using Robinhood data, and it’s not a recommendation.